Esophageal Cancer



The epidemiology of esophageal cancer has marked variations in different areas of the world. The two major types are squamous and adenocarcinoma, the latter entity has attracted much attention because of increasing prevalence in the Western nations. The major risk factors for adenocarcinoma include long-standing gastroesophageal reflux disease, Barrett’s metaplasia, obesity, and possibly ethnicity in view of the observation that it affects predominantly Caucasian men. Risk factors for squamous carcinoma include alcoholism and smoking. Manifestations include dysphagia to solids and liquids, weight loss, and aspiration. Diagnosis requires upper endoscopy and target biopsies. Staging requires endoscopic ultrasound and CT imaging of chest and abdomen. Management includes surgery, chemotherapy, and chemoradiation, based on location, stage and type of cancer, in addition to age and comorbidity.


Vascular Endothelial Growth Factor Esophageal Cancer Esophageal Carcinoma Peptic Esophagitis Carbon Black Exposure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907.PubMedCrossRefGoogle Scholar
  4. 4.
    American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society; 2010.Google Scholar
  5. 5.
    Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Accessed 26 July 2011.
  6. 6.
    Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009;38:27–57, vii.Google Scholar
  12. 12.
    Pottern LM, Morris LE, Blot WJ, Ziegler RG, Fraumeni Jr JF. Esophageal cancer among black men in Washington, D.C. I. Alcohol, tobacco, and other risk factors. J Natl Cancer Inst. 1981;67:777–83.PubMedGoogle Scholar
  13. 13.
    Tougeron D, Hamidou H, Scotte M, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510.PubMedCrossRefGoogle Scholar
  14. 14.
    Nordenstedt H, El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992–2006). Scand J Gastroenterol. 2011;46:597–602.PubMedCrossRefGoogle Scholar
  15. 15.
    Morganstern B, Anandasabapathy S. GERD and Barrett’s esophagus: diagnostic and management strategies in the geriatric population. Geriatrics. 2009;64:9–12.PubMedGoogle Scholar
  16. 16.
    Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–95.PubMedCrossRefGoogle Scholar
  17. 17.
    Goldblum JR. Barrett’s esophagus and Barrett’s-related dysplasia. Mod Pathol. 2003;16:316–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Spechler SJ, Barr H. Review article: screening and surveillance of Barrett’s oesophagus: what is a cost-effective framework? Aliment Pharmacol Ther. 2004;19 Suppl 1:49–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Takubo K, Vieth M, Aida J, et al. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion. 2009;80:248–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109:1541–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett’s oesophagus: an overrated risk. Gut. 1989;30:14–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106(8):1447–55.PubMedCrossRefGoogle Scholar
  24. 24.
    Pandeya N, Williams GM, Sadhegi S, Green AC, Webb PM, Whiteman DC. Associations of duration, intensity, and quantity of smoking with adenocarcinoma and squamous cell carcinoma of the esophagus. Am J Epidemiol. 2008;168:105–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen ZM, Xu Z, Collins R, Li WX, Peto R. Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA. 1997;278:1500–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Randi G, Scotti L, Bosetti C, et al. Pipe smoking and cancers of the upper digestive tract. Int J Cancer. 2007;121:2049–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999;340:1773–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Druesne-Pecollo N, Tehard B, Mallet Y, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol. 2009;10:173–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Islami F, Ren JS, Taylor PR, Kamangar F. Pickled vegetables and the risk of oesophageal cancer: a meta-analysis. Br J Cancer. 2009;101:1641–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Wang L, Zhu D, Zhang C, et al. Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China. Int J Cancer. 1997;71:719–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Chu FS, Li GY. Simultaneous occurrence of fumonisin B1 and other mycotoxins in moldy corn collected from the People’s Republic of China in regions with high incidences of esophageal cancer. Appl Environ Microbiol. 1994;60:847–52.PubMedGoogle Scholar
  33. 33.
    Pickwell SM, Schimelpfening S, Palinkas LA. ‘Betelmania’. Betel quid chewing by Cambodian women in the United States and its potential health effects. West J Med. 1994;160:326–30.PubMedGoogle Scholar
  34. 34.
    Trivedy C, Baldwin D, Warnakulasuriya S, Johnson N, Peters T. Copper content in Areca catechu (betel nut) products and oral submucous fibrosis. Lancet. 1997;349:1447.PubMedCrossRefGoogle Scholar
  35. 35.
    Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-temperature beverages and foods and esophageal cancer risk—a systematic review. Int J Cancer. 2009;125:491–524.PubMedCrossRefGoogle Scholar
  36. 36.
    Cross AJ, Freedman ND, Ren J, et al. Meat consumption and risk of esophageal and gastric cancer in a large prospective study. Am J Gastroenterol. 2011;106:432–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 2010;138:1704–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Abnet CC, Lai B, Qiao YL, et al. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J Natl Cancer Inst. 2005;97:301–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology. 2006;131:1271–83.PubMedCrossRefGoogle Scholar
  40. 40.
    Bravi F, Edefonti V, Randi G, et al. Dietary patterns and the risk of esophageal cancer. Ann Oncol. 2012;23(3):765–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Sandler RS, Nyren O, Ekbom A, Eisen GM, Yuen J, Josefsson S. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. 1995;274:1359–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Stevens HP, Kelsell DP, Bryant SP, et al. Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol. 1996;132:640–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211.PubMedGoogle Scholar
  44. 44.
    Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett’s esophagus. Am J Gastroenterol. 2008;103:292–300.PubMedCrossRefGoogle Scholar
  45. 45.
    Parent ME, Siemiatycki J, Fritschi L. Workplace exposures and oesophageal cancer. Occup Environ Med. 2000;57:325–34.PubMedCrossRefGoogle Scholar
  46. 46.
    Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer—a pathway through the confusion. Nat Rev Rheumatol. 2011;7:369–72.PubMedCrossRefGoogle Scholar
  47. 47.
    Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562–72; discussion 72–3.Google Scholar
  48. 48.
    Coia LR, Sauter ER. Esophageal cancer. Curr Probl Cancer. 1994;18:189–247.PubMedCrossRefGoogle Scholar
  49. 49.
    Lagergren J, Lagergren P. Oesophageal cancer. BMJ. 2010;341:c6280.PubMedCrossRefGoogle Scholar
  50. 50.
    Gross SA, Raimondo M, Conio M. Upper gastrointestinal tumors. Endoscopy. 2007;39:110–2.PubMedCrossRefGoogle Scholar
  51. 51.
    Kuipers EJ, Haringsma J. Diagnostic and therapeutic endoscopy. J Surg Oncol. 2005;92:203–9.PubMedCrossRefGoogle Scholar
  52. 52.
    van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547–57.PubMedCrossRefGoogle Scholar
  53. 53.
    Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol. 2005;23:4483–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Yau KK, Siu WT, Cheung HY, Li AC, Yang GP, Li MK. Immediate preoperative laparoscopic staging for squamous cell carcinoma of the esophagus. Surg Endosc. 2006;20:307–10.PubMedCrossRefGoogle Scholar
  55. 55.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC staging manual. 7th ed. New York: Springer; 2009.Google Scholar
  56. 56.
    Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507–12.PubMedCrossRefGoogle Scholar
  57. 57.
    Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894–902.PubMedCrossRefGoogle Scholar
  58. 58.
    Daly JM, Karnell LH, Menck HR. National cancer data base report on esophageal carcinoma. Cancer. 1996;78:1820–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg. 1999;230:392–400; discussion 400−3.Google Scholar
  60. 60.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRefGoogle Scholar
  62. 62.
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.PubMedCrossRefGoogle Scholar
  64. 64.
    O’Reilly S, Forastiere AA. Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol. 1995;6:519–21.PubMedGoogle Scholar
  65. 65.
    Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.PubMedGoogle Scholar
  66. 66.
    Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001;19:1970–5.PubMedGoogle Scholar
  67. 67.
    Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg. 1999;117:16–23; discussion 23–5.Google Scholar
  68. 68.
    Kato H, Tachimori Y, Watanabe H, et al. Intramural metastasis of thoracic esophageal carcinoma. Int J Cancer. 1992;50:49–52.PubMedCrossRefGoogle Scholar
  69. 69.
    Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus. 2011;24:33–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Barreto JC, Posner MC. Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010;16:3804–10.PubMedCrossRefGoogle Scholar
  71. 71.
    Herskovic A, Martz K, al-Sarraf M. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.PubMedCrossRefGoogle Scholar
  72. 72.
    al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277–84.PubMedGoogle Scholar
  73. 73.
    Wobbes T, Baron B, Paillot B, et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer. 2001;37:470–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer. 1980;46:2149–53.PubMedCrossRefGoogle Scholar
  75. 75.
    Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Kok TC, van der Gaast A, Splinter TA. 5-Fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Ann Oncol. 1996;7:533–4.PubMedCrossRefGoogle Scholar
  77. 77.
    Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18:898–902.PubMedCrossRefGoogle Scholar
  78. 78.
    Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Warner E, Jensen JL, Cripps C, et al. Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol. 1999;38:255–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5:609–16.PubMedGoogle Scholar
  82. 82.
    Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Elsayed H, Whittle I, McShane J, et al. The influence of age on mortality and survival in patients undergoing oesophagogastrectomies. A seven-year experience in a tertiary centre. Interact Cardiovasc Thorac Surg. 2010;11:65–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Honore C, Al-Azzeh A, Gilson N, et al. Esophageal cancer surgery in patients older than 75: long term results. Acta Chir Belg. 2011;111:12–7.PubMedGoogle Scholar
  85. 85.
    Zehetner J, Lipham JC, Ayazi S, et al. Esophagectomy for cancer in octogenarians. Dis Esophagus. 2010;23:666–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.PubMedCrossRefGoogle Scholar
  88. 88.
    De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 2010;36 Suppl 3:S11–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18:510–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667–73.PubMedCrossRefGoogle Scholar
  92. 92.
    Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol. 2006;24:1612–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res. 2007;13:5869–75.PubMedCrossRefGoogle Scholar
  94. 94.
    Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Gerger A, LaBonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J. 2011;17(2):134–41.PubMedCrossRefGoogle Scholar
  96. 96.
    Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011;103:468–74.PubMedCrossRefGoogle Scholar
  97. 97.
    Janjigian YY, Shah MA. Molecularly targeted therapies in advanced gastric cancer. Minerva Gastroenterol Dietol. 2011;57:75–88.PubMedGoogle Scholar
  98. 98.
    Damasceno M. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Curr Opin Oncol. 2011;23(Suppl):S3–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). ASCO Meeting Abstracts. 28:LBA4007.Google Scholar
  100. 100.
    Keld RR, Ang YS. Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine? World J Gastroenterol. 2011;17:2781–90.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of OncologyMontefiore Medical Center (North Division)BronxUSA

Personalised recommendations